| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.rpglifesciences.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 841.42 Cr. | |
| Earnings per share (EPS) | 26.92 | Trailing Twelve Months Ending 2021-06 |
| Price-Earning Ratio (PE) | 18.90 | Trailing Twelve Months Ending 2021-06 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-06 |
| Book Value / Share | 139.08 | Trailing Twelve Months Ending 2021-06 |
| Price to Book Value | 3.66 | Calculated using Price: 508.75 |
| Dividend Yield | 1.42 | Period Ending 2020-03 |
| No. of Shares Subscribed | 1.65 Cr. | 16,539,015 Shares |
| FaceValue | 8 | |
| Company Profile | ||
|
RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide. The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business. RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia. Major Activities of the Company:
Company’s Patnership: It is represented in over thirty countries through strategic partnerships and joint ventures.
Achievements:
|
||
Company Profile
RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group
RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.
The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.
RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.
Major Activities of the Company:
Company’s Patnership:
It is represented in over thirty countries through strategic partnerships and joint ventures.
Achievements:
| 1 Day |
|
-0.15% |
| 1 Week |
|
+10.93% |
| 1 Month |
|
+13.03% |
| 3 Month |
|
+5.80% |
| 6 Month |
|
+26.42% |
| 1 Year |
|
+60.84% |
| 2 Year |
|
+146.28% |
| 5 Year |
|
+31.99% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 1.14 | 5.87 | 52.87 | 0.80 | 8.98 | 14.98 | 8.91 | 6.86 | 17.21 | |
| Return on Capital Employed (%) | 6.73 | 5.99 | 48.37 | 2.50 | 8.97 | 15.58 | 12.52 | 9.81 | 20.35 | |
| Return on Assets (%) | 0.44 | 2.21 | 25.50 | 0.47 | 5.34 | 9.15 | 5.17 | 4.07 | 11.25 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 74 | 76 | 126 | 125 | 134 | 147 | 155 | 161 | 177 | |
| Non Curr. Liab. | 42 | 22 | 7 | 20 | 22 | 11 | 8 | 10 | 9 | |
| Curr. Liab. | 73 | 112 | 77 | 67 | 67 | 79 | 121 | 78 | 83 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 189 | 210 | 209 | 212 | 223 | 236 | 284 | 248 | 268 | |
| Non Curr. Assets | 120 | 111 | 112 | 126 | 136 | 140 | 141 | 151 | 142 | |
| Curr. Assets | 69 | 99 | 97 | 86 | 87 | 96 | 143 | 97 | 126 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 189 | 210 | 209 | 212 | 223 | 236 | 284 | 248 | 268 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 193 | 222 | 236 | 242 | 279 | 294 | 344 | 330 | 376 | |
| Other Income | 1 | 2 | 3 | 7 | 2 | 10 | 2 | 1 | 1 | |
| Total Income | 194 | 224 | 238 | 249 | 281 | 303 | 346 | 331 | 377 | |
| Total Expenditure | -175 | -206 | -224 | -234 | -257 | -265 | -307 | -296 | -316 | |
| PBIDT | 19 | 18 | 14 | 15 | 24 | 38 | 39 | 35 | 61 | |
| Interest | -7 | -7 | -3 | -3 | -2 | -4 | -5 | -5 | -3 | |
| Depreciation | -10 | -10 | -11 | -11 | -10 | -11 | -14 | -15 | -16 | |
| Taxation | -1 | 4 | -12 | -2 | -7 | -4 | -7 | |||
| Exceptional Items | 64 | -5 | ||||||||
| PAT | 1 | 4 | 53 | 1 | 12 | 21 | 13 | 11 | 29 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 16 | 12 | -6 | -2 | 33 | 7 | 15 | 46 | 50 | |
| Cash Fr. Inv. | -8 | -12 | 59 | -10 | -15 | -30 | -16 | -19 | -11 | |
| Cash Fr. Finan. | -8 | 0 | -54 | 12 | -18 | 23 | 0 | -27 | -39 | |
| Net Change | 0 | 0 | 0 | 0 | 1 | -1 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
|
Thu, 29 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith a copy of the newspaper publications with respect to Unaudited Financial Results for the quarter ended June 30 2021. Kindly take this information on record. |
|
Wed, 28 Jul 2021
Unaudited Financial Result For The Quarter Ended June 30 2021 Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Unaudited Financial Results for the quarter ended June 30 2021 which were approved by the Board of Directors of the Company at its meeting held on July 28 2021 along with Limited Review Report issued by the Statutory Auditors of the Company. The meeting commenced at 03:00 p.m. and concluded at 05:00 p.m. Kindly take the above on your record. |
|
Wed, 28 Jul 2021
Board Meeting Outcome for Outcome Of Board Meeting Held On July 28 2021 In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of the Company has at its meeting held on Wednesday July 28 2021 inter alia considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30 2021 along with Limited Review Report of the Statutory Auditors thereon. The meeting commenced at 03:00 p.m. and concluded at 05:00 p.m. Kindly take the same on your record. |
| Fri, 30 Jul 2021 |
Increasing Relative Strength - Benchmark index
|
Close Within 2 Year High Zone
|
Both SRS And ARS Above Zero
|
ATR Increasing for 3 Days
|
Stochastic %K Crossing %D from Above
|
Equities
M.F.
Sectors